Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy of ZA oral solution in subjects with IRD caused by biallelic recessive RPE65 or LRAT gene mutations and phenotypically diagnosed as Leber's Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04311112
Study type Interventional
Source Retinagenix Holdings
Contact
Status Withdrawn
Phase Phase 2/Phase 3
Start date December 2020
Completion date September 2023

See also
  Status Clinical Trial Phase
Completed NCT01815567 - DETECT and Retinal Outcomes in Hypertension